Skip to content
Research/Longevity Diagnostics/Targeted Genotyping of PNPLA3 and HSD17B13

Targeted Genotyping of PNPLA3 and HSD17B13

Targeted genotyping of PNPLA3 rs738409 and HSD17B13 rs72613567 involves analyzing specific genetic variants associated with liver health. These variants can influence the risk of liver disease, making them important for personalized health strategies and longevity optimization. Understanding these genetic markers can help tailor interventions to mitigate liver-related health risks.

Intelligence Profile

Research Papers

Research on targeted genotyping of PNPLA3 and HSD17B13 has explored their roles in liver diseases, particularly Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

  1. Genome-Wide Association Studies and Functional Interpretation:
    The study titled "Genome-Wide Association Studies in Hepatocellular Carcinoma: Aetiology-Specific Susceptibility, Functional Interpretation, and Clinical Translation" (Genes, 2026) examines how specific genetic variants, including those in PNPLA3 and HSD17B13, could influence susceptibility to liver diseases like hepatocellular carcinoma. Though detailed data is not presented, the study emphasizes the importance of understanding genetic risk to improve clinical outcomes.

  2. Monogenic and Polygenic Risk in Liver Diseases:
    In the article "Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care" (Gastroenterology, 2026), researchers discuss the significant influence of genetic variants on liver disease risk, highlighting PNPLA3 as a major risk factor for fatty liver diseases through polygenic risk scores.

  3. Genetic Predisposition to MASLD:
    "Genetic Predisposition to MASLD: Potential for Therapeutic Management" (Int J Mol Sci, 2026) suggests targeted genotyping could help tailor therapeutic interventions for individuals at high genetic risk, identifying PNPLA3 and HSD17B13 as key targets for potential therapy adjustments.

  4. High Inherited Risk and Fibrosis Progression:
    The research "High inherited risk predicts age-associated increases in fibrosis in patients with MASLD" (J Hepatol, 2025) underscores the utility of genetic information, including PNPLA3 genotyping, to predict disease progression, specifically noting the connection between genetic risk and fibrosis.

  5. Genetic Risk Factors for MASLD:
    The "Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease" (Gut Liver, 2025) study reiterates the importance of PNPLA3 and HSD17B13 in disease manifestation, suggesting these genes significantly contribute to disease development and progression.

  6. Inconclusive Effects in Indian Population:
    A study titled "17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population" (J Clin Exp Hepatol, 2024) indicates that not all genetic variants have consistent effects across populations. Here, HSD17B13 did not show protective effects against NAFLD, suggesting population-specific genetic influences.

The ongoing clinical trial "Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS)" may provide additional insights into genetic influences, though it is not yet recruiting.

Overall, while targeted genotyping of PNPLA3 and HSD17B13 shows promise in understanding liver diseases and guiding clinical care, effects can vary across populations, and more research is needed to refine their roles in therapy.

Disclaimer: This summary is for informational purposes only and is not a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.